reverse-phase HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-03. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
The most common tumor affecting the thyroid is a benign adenoma, usually presenting as a painless mass in the neck. Thyroid cancers are most often carcinomas, although cancer can occur in any tissue that the thyroid consists of, including cancer of C-cells and lymphomas. Cancers from other sites also rarely lodge in the thyroid. Radiation of the head and neck presents a risk factor for thyroid cancer, and cancer is more common in women than men, occurring at a rate of about 2:1. In most cases, thyroid cancer presents as a painless mass in the neck. It is very unusual for thyroid cancers to present with other symptoms, although in some cases cancer may cause hyperthyroidism. Most thyroid cancers are papillary, followed by follicular, medullary, and thyroid lymphoma. Because of the prominence of the thyroid gland, cancer is often detected earlier in the course of disease as the cause of a nodule, which may undergo fine-needle aspiration. Thyroid function tests will help reveal whether the nodule produces excess thyroid hormones. A radioactive iodine uptake test can help reveal the activity and location of the cancer and metastases. Thyroid cancers are treated by removing the whole or part of thyroid gland. Radioactive iodine-131 may be given to radioablate the thyroid. Thyroxine is given to replace the hormones lost and to suppress TSH production, as TSH may stimulate recurrence. With the exception of the rare anaplastic thyroid cancer, which carries a very poor prognosis, most thyroid cancers carry an excellent prognosis and can even be considered curable.
=== Preadaptation model === The preadaptation model of de novo gene birth uses mathematical modeling to show that when sequences that are normally hidden are exposed to weak or shielded selection, the resulting pool of "cryptic" sequences (i.e. proto-genes) can be purged of "self-evidently deleterious" variants, such as those prone to lead to protein aggregation, and thus enriched in potential adaptations relative to a completely non-expressed and unpurged set of sequences. This revealing and purging of cryptic deleterious non-genic sequences is a byproduct of pervasive transcription and translation of intergenic sequences, and is expected to facilitate the birth of functional de novo protein-coding genes. This is because by eliminating the most deleterious variants, what is left is, by a process of elimination, more likely to be adaptive than expected from random sequences. Using the evolutionary definition of function (i.e. that a gene is by definition under purifying selection against loss), the preadaptation model assumes that "gene birth is a sudden transition to functionality" that occurs as soon as an ORF acquires a net beneficial effect. In order to avoid being deleterious, newborn genes are expected to display exaggerated versions of genic features associated with the avoidance of harm. This is in contrast to the proto-gene model, which expects newborn genes to have features intermediate between old genes and non-genes.
=== Color of transition metal complexes === Transition metal complexes often have spectacular colors caused by electronic transitions by the absorption of light. For this reason they are often applied as pigments. Most transitions that are related to colored metal complexes are either d–d transitions or charge transfer bands. In a d–d transition, an electron in a d orbital on the metal is excited by a photon to another d orbital of higher energy, therefore d–d transitions occur only for partially-filled d-orbital complexes (d1–9). For complexes having d0 or d10 configuration, charge transfer is still possible even though d–d transitions are not. A charge transfer band entails promotion of an electron from a metal-based orbital into an empty ligand-based orbital (metal-to-ligand charge transfer or MLCT). The converse also occurs: excitation of an electron in a ligand-based orbital into an empty metal-based orbital (ligand-to-metal charge transfer or LMCT). These phenomena can be observed with the aid of electronic spectroscopy; also known as UV-Vis. For simple compounds with high symmetry, the d–d transitions can be assigned using Tanabe–Sugano diagrams. These assignments are gaining increased support with computational chemistry.
=== Uncompetitive === In uncompetitive inhibition the inhibitor binds only to the enzyme-substrate complex. This type of inhibition causes Vmax to decrease (maximum velocity decreases as a result of removing activated complex) and Km to decrease (due to better binding efficiency as a result of Le Chatelier's principle and the effective elimination of the ES complex thus decreasing the Km which indicates a higher binding affinity). Uncompetitive inhibition is rare.
Sources: en.wikipedia.org
=== 23 February === The Russian Ministry of Defense claimed that Ukraine was preparing to invade Transnistria and that Russian soldiers there would respond accordingly. Moldovan authorities pushed back against these claims.
Currently, FDA have already approved a number of diagnostics assays utilizing microarrays: Agendia's MammaPrint assays can inform the breast cancer recurrence risk by profiling the expression of 70 genes related to breast cancer; Autogenomics INFNITI CYP2C19 assay can profile genetic polymorphisms, whose impacts on therapeutic response to antidepressants are great; and Affymetrix's CytoScan Dx can evaluate intellectual disabilities and congenital disorders by analyzing chromosomal mutation. In the future, the diagnostic tools for cancer will likely to focus on the Next Generation Sequencing (NGS). By utilizing DNA and RNA sequencing to do cancer diagnostics, technology in the field of molecular diagnostics tools will develop better. Although NGS throughput and price have dramatically been reduced over the past 10 years by roughly 100-fold, we remain at least 6 orders of magnitude away from performing deep sequencing at a whole genome level. Currently, Ion Torrent developed some NGS panels based on translational AmpliSeq, for example, the Oncomine Comprehensive Assay. They are focusing on utilizing deep sequencing of cancer-related genes to detect rare sequence variants. Molecular diagnostics tool can be used for cancer risk assessment. For example, the BRCA1/2 test by Myriad Genetics assesses women for lifetime risk of breast cancer. Also, some cancers are not always employed with clear symptoms. It is useful to analyze people when they do not show obvious symptoms and thus can detect cancer at early stages.
National legislation for amendment of the Controlled Substances Act to place salvinorin A and Salvia divinorum in Schedule I at the federal level in the United States was proposed in 2002 by Representative Joe Baca (D- California). Those opposed to bill HR 5607 include Daniel Siebert, who sent a letter to Congress arguing against the proposed legislation, and the Center for Cognitive Liberty and Ethics (CCLE), who sent key members of the US Congress a report on Salvia divinorum and its active principle, along with letters from an array of scientists who expressed concern that scheduling Salvia divinorum would negatively impact important research on the plant. The bill did not pass. Although salvia is not regulated under the Controlled Substances Act, as of 2009, it had been made illegal in 13 states. Delaware banned it after salvia use was reported to have played a role in the suicide of a teenager. Alabama, Delaware, Illinois, Louisiana, Michigan, Missouri, Ohio, Texas, and other states have passed their own laws. Several other states have proposed legislation against salvia, including Alaska, California, Florida, Iowa, Maryland, New Jersey, New York, Oregon, and Pennsylvania. Many of these proposals have not made it into law, with motions having failed, stalled or otherwise died, for example at committee review stages. Where individual state legislation does exist, it varies from state to state in its prohibitive degree. Legal consequences may also exist even in states without bans on salvia in particular.
== Regulation == In Europe, regulation is currently split into three areas of regulation: medical devices, medicinal products, and biologics. Tissue engineering products are often of hybrid nature, as they are often composed of cells and a supporting structure. While some products can be approved as medicinal products, others need to gain approval as medical devices. Derksen explains in her thesis that tissue engineering researchers are sometimes confronted with regulation that does not fit the characteristics of tissue engineering. New regulatory regimes have been observed in Europe that tackle these issues. An explanation for the difficulties in finding regulatory consensus in this matter is given by a survey conducted in the UK. The authors attribute these problems to the close relatedness and overlap with other technologies such as xenotransplantation. It can therefore not be handled separately by regulatory bodies. Regulation is further complicated by the ethical controversies associated with this and related fields of research (e.g. stem cells controversy, ethics of organ transplantation). The same survey as mentioned above shows on the example of autologous cartilage transplantation that a specific technology can be regarded as 'pure' or 'polluted' by the same social actor. Two regulatory movements are most relevant to tissue engineering in the European Union.
Famous examples of modern anthropomorphic taxidermy include the work of artist Adele Morse, who gained international attention with her "Stoned Fox" sculpture series, and the work of artist Sarina Brewer, known for her Siamese twin squirrels and flying monkeys partaking in human activities.
Sources: en.wikipedia.org
For South Africa and the Soviet Union—the two parties which had previously refrained from joining the US-mediated talks—the point had now been reached where the costs of continuing the war exceeded its anticipated benefits. This necessitated a change in perceptions in both nations, which began warming to the possibility of a negotiated peace. The Soviet government agreed to jointly sponsor with the US a series of renewed peace talks on 3 and 4 May 1988. For its part, South Africa made its first bid to join the tripartite negotiations and agreed to send a delegation of diplomats, intelligence chiefs, and senior SADF officers. The Soviet and US diplomats in attendance, including Crocker, made it clear to the South Africans that they wanted peace in Angola and a political settlement in South West Africa. They were also agreed on the need to bring pressure on their respective allies to bring about a solution. South Africa would be expected to comply with United Nations Security Council Resolution 435, in exchange for the complete withdrawal of Cuban troops from Angola. The Cuban and Angolan delegations had already assented to a complete Cuban withdrawal, and under US pressure produced an extremely precise timetable which extended this process over three to four years. South Africa found this unacceptable but conceded that the withdrawal could be timed to certain benchmarks in the Namibian independence process. According to Crocker, the US decision to use Security Council Resolution 435 as the basis and pivot for a regional settlement provided leverage over the discussions.
operon A functional unit of gene expression consisting of a cluster of neighboring structural genes which are collectively under the control of a single promoter, along with one or more adjacent regulatory sequences such as operators. The set of genes is transcribed together, resulting in a single polycistronic messenger RNA molecule encoding multiple distinct polypeptides which may then be translated together or undergo splicing to create multiple mRNAs which are translated independently; the result is that the genes contained in the operon are either expressed together or not at all. Regulatory proteins, including repressors and activators, usually bind specifically to the regulatory sequences of a given operon; by some definitions, the genes that code for these regulatory proteins are also considered part of the operon.
Tolkien wrote a brief "Sketch of the Mythology", which included the tales of Beren and Lúthien and of Túrin; and that sketch eventually evolved into the Quenta Silmarillion, an epic history that Tolkien started three times but never published. Tolkien desperately hoped to publish it along with The Lord of the Rings, but publishers (both Allen & Unwin and Collins) declined. Moreover, printing costs were very high in 1950s Britain, requiring The Lord of the Rings to be published in three volumes. The story of this continuous redrafting is told in the posthumous series The History of Middle-earth, edited by Tolkien's son, Christopher Tolkien. From around 1936, Tolkien began to extend this framework to include the tale of The Fall of Númenor, which was inspired by the legend of Atlantis. Tolkien appointed his son Christopher to be his literary executor, and he (with assistance from Guy Gavriel Kay, later a well-known fantasy author in his own right) organized some of this material into a single coherent volume, published as The Silmarillion in 1977. It received the Locus Award for Best Fantasy novel in 1978.
== Life == Ogston was educated at Eton College and Balliol College, Oxford. Apart from a period as Freedom Research Fellow at the London Hospital, he spent most of his career at Oxford, being appointed Demonstrator (1938) and Reader (1955) in Biochemistry, and Fellow and Tutor in Physical Chemistry at Balliol (1937). In that capacity he had a major influence on other distinguished scientists, such as the Nobel prizewinner Oliver Smithies, who wrote his first paper with him, and Richard Dawkins, who chose to study zoology on his recommendation. In 1959 he took up an appointment as Professor of Physical Biochemistry at the John Curtin School of Medical Research at the Australian National University (ANU), Canberra, where he remained until 1970, when he returned to Oxford as President of Trinity College. On his retirement in 1978, he held visiting fellowships at the Institute for Cancer Research, Philadelphia and the John Curtin School of Medical Research, ANU. Ogston was elected FRS in 1955, and was awarded Lemberg Medal in 1970 and the Davy Medal in 1986.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.